1. Home
  2. VGZ vs TRDA Comparison

VGZ vs TRDA Comparison

Compare VGZ & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vista Gold Corp

VGZ

Vista Gold Corp

HOLD

Current Price

$1.90

Market Cap

316.8M

Sector

N/A

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$7.37

Market Cap

274.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VGZ
TRDA
Founded
1983
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
316.8M
274.5M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
VGZ
TRDA
Price
$1.90
$7.37
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$3.75
$21.00
AVG Volume (30 Days)
3.0M
279.1K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$25,421,000.00
Revenue This Year
N/A
$39.97
Revenue Next Year
N/A
$50.80
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.91
$4.93
52 Week High
$3.13
$16.45

Technical Indicators

Market Signals
Indicator
VGZ
TRDA
Relative Strength Index (RSI) 37.45 50.31
Support Level $1.79 $5.75
Resistance Level $2.42 $10.82
Average True Range (ATR) 0.15 0.52
MACD -0.05 0.26
Stochastic Oscillator 6.13 77.36

Price Performance

Historical Comparison
VGZ
TRDA

About VGZ Vista Gold Corp

Vista Gold Corp operates as a development-stage company in the gold mining industry. Its flagship asset is the Mt Todd Gold Project, a development-stage gold deposit located in the Tier-1 jurisdiction of Northern Territory, Australia. Mt Todd offers a large gold mineral reserve, development optionality, expansion opportunities, exploration upside, local infrastructure, community support, and demonstrated economic feasibility. It operates in one reportable segment, consisting of acquisition, exploration and evaluation activities which are focused on Australia.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: